{"id":1016387,"date":"2026-11-02T17:16:23","date_gmt":"2026-11-02T22:16:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/"},"modified":"2026-11-02T17:16:23","modified_gmt":"2026-11-02T22:16:23","slug":"spero-therapeutics-to-present-at-investor-conferences-in-november","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/","title":{"rendered":"Spero Therapeutics to Present at Investor Conferences in November"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Nov.  02, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I2v77ch0D93X-dbft3cNmovTQ7pjzD7C-1An_PeTBQIt-1T6-3xnpDPpl1f8Eb8LGNcYtFMb38BcnRBfkZcN7rA0lRVXAqu1oml3WyrkZJg=\" rel=\"nofollow\" target=\"_blank\">Spero Therapeutics, Inc.<\/a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a \u201cfireside chat\u201d at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company&#8217;s leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"vertical-align: top\">\n            <strong>Guggenheim 3rd Annual Healthcare Innovation Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: top\">Date:<\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%;vertical-align: top\">Tuesday, November 10<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Time:<\/td>\n<td style=\"vertical-align: top\">10:30 AM ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Location:<\/td>\n<td style=\"vertical-align: top\">Boston, MA<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Webcast Link:<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/event.summitcast.com\/view\/oVDtKqmPn2tPc7VV7WsLAC\/LYEeYjHcVGZSaLAc2q5G2q\" rel=\"nofollow\" target=\"_blank\">click here<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\">\n            <strong>Jefferies Global Healthcare Conference <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%\">Dates:<\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%\">November 18-19<\/td>\n<\/tr>\n<tr>\n<td>Location:<\/td>\n<td>London, UK<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>To request a meeting with management please reach out to your institutional contact at the respective conference.<\/p>\n<p>\n        <strong>About Spero Therapeutics<\/strong>\n      <\/p>\n<p>Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company\u2019s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological &amp; inflammatory diseases. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SbQ2X62Xwk0ILf44g5eXWF8xyvvyGQhRhjnjexDeSantxKuu4ptAbo6e4OP_S_C4LtrWuYad2WSZcdZ8qLWrYA==\" rel=\"nofollow\" target=\"_blank\">www.sperotx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Shai Biran, PhD<br \/>Spero Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0DJGRpgxVoHHiC8N6bHEFMZUjLyPwyQABzt2qZ6Cv37zknC5o26JP7B702_fTTi3swVjLZv8_Pdju5oEJV7ymA==\" rel=\"nofollow\" target=\"_blank\">IR@Sperotx.com<\/a><\/p>\n<p>\n        <strong>Media Inquiries:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f439Ibbwiy2b6K4fTkUMBTU1HsnzdCQZTyEI9yio2c-DSYvh58sYbE32wQGtB78GVoBNv1fanoIQwUML9R4wX5tL9Dkzu4aazZ6GqQK1VuE=\" rel=\"nofollow\" target=\"_blank\">media@sperotx.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTc2MjRiMDctMzRhZi00MTUzLTk3MjYtMjBhMjYzNDUwYzgxLTExMDE5MzMtMjAyNi0xMS0wMi1lbg==\/tiny\/Spero-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a \u201cfireside chat\u201d at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company&#8217;s leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors. Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10 Time: 10:30 AM ET Location: Boston, MA Webcast Link: click here Jefferies Global Healthcare Conference Dates: November 18-19 Location: London, UK To request &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spero Therapeutics to Present at Investor Conferences in November&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016387","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spero Therapeutics to Present at Investor Conferences in November - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spero Therapeutics to Present at Investor Conferences in November - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a \u201cfireside chat\u201d at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company&#8217;s leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors. Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10 Time: 10:30 AM ET Location: Boston, MA Webcast Link: click here Jefferies Global Healthcare Conference Dates: November 18-19 Location: London, UK To request &hellip; Continue reading &quot;Spero Therapeutics to Present at Investor Conferences in November&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T22:16:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spero Therapeutics to Present at Investor Conferences in November\",\"datePublished\":\"2026-11-02T22:16:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/\"},\"wordCount\":215,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/\",\"name\":\"Spero Therapeutics to Present at Investor Conferences in November - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=\",\"datePublished\":\"2026-11-02T22:16:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-at-investor-conferences-in-november\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spero Therapeutics to Present at Investor Conferences in November\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spero Therapeutics to Present at Investor Conferences in November - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/","og_locale":"en_US","og_type":"article","og_title":"Spero Therapeutics to Present at Investor Conferences in November - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a \u201cfireside chat\u201d at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company&#8217;s leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors. Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10 Time: 10:30 AM ET Location: Boston, MA Webcast Link: click here Jefferies Global Healthcare Conference Dates: November 18-19 Location: London, UK To request &hellip; Continue reading \"Spero Therapeutics to Present at Investor Conferences in November\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-02T22:16:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spero Therapeutics to Present at Investor Conferences in November","datePublished":"2026-11-02T22:16:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/"},"wordCount":215,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/","name":"Spero Therapeutics to Present at Investor Conferences in November - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=","datePublished":"2026-11-02T22:16:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODQyNiM3OTQwNzUxIzIwOTAzNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-at-investor-conferences-in-november\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spero Therapeutics to Present at Investor Conferences in November"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016387"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016387\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}